Ocular Therapeutix Inc’s filing revealed that its Chief Scientific Officer Heier Jeffrey S. unloaded Company’s shares for reported $26561.0 on Nov 25 ’24. In the deal valued at $9.01 per share,2,948 shares were sold. As a result of this transaction, Heier Jeffrey S. now holds 269,059 shares worth roughly $2.11 million.
Then, Kaiser Peter sold 2,897 shares, generating $26,102 in total proceeds. Upon selling the shares at $9.01, the Chief Development Officer now owns 213,087 shares.
Before that, Nayak Sanjay sold 1,814 shares. Ocular Therapeutix Inc shares valued at $16,326 were divested by the Chief Strategy Officer at a price of $9.00 per share. As a result of the transaction, Nayak Sanjay now holds 174,380 shares, worth roughly $1.37 million.
Scotiabank initiated its Ocular Therapeutix Inc [OCUL] rating to a Sector outperform in a research note published recently. A number of analysts have revised their coverage, including TD Cowen’s analysts, who increased its forecast for the stock in mid June from “a Hold” to “a Buy”. BofA Securities started covering the stock on February 09, 2024. It rated OCUL as “a Buy”.
Price Performance Review of OCUL
On Tuesday, Ocular Therapeutix Inc [NASDAQ:OCUL] saw its stock fall -3.20% to $7.86. Over the last five days, the stock has lost -11.49%. Ocular Therapeutix Inc shares have fallen nearly -7.96% since the year began. Nevertheless, the stocks have risen 78.23% over the past one year. While a 52-week high of $11.77 was reached on 01/07/25, a 52-week low of $3.76 was recorded on 01/14/25. SMA at 50 days reached $9.29, while 200 days put it at $8.09.
Levels Of Support And Resistance For OCUL Stock
The 24-hour chart illustrates a support level at 7.56, which if violated will result in even more drops to 7.26. On the upside, there is a resistance level at 8.30. A further resistance level may holdings at 8.73. The Relative Strength Index (RSI) on the 14-day chart is 34.26, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.46, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 89.18%. Stochastics %K at 16.80% indicates the stock is a buying.
How much short interest is there in Ocular Therapeutix Inc?
A steep rise in short interest was recorded in Ocular Therapeutix Inc stocks on 2024-10-31, dropping by -3.52 million shares to a total of 12.67 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 16.19 million shares. There was a decline of -27.8%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 21, 2023 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $18 price target.
